Obagi Medical Partners with Alpha Aesthetic Partners for ALOHA Program (NASDAQ:WALD)

NEW YORK and SACRAMENTO, Calif. — January 27, 2026 — Leads & Copy — Obagi Medical, part of Waldencast plc (NASDAQ: WALD), has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi‘s Hyaluronic Acid (ALOHA) Program.

Alpha was chosen as an ALOHA launch partner because of its commitment to innovation, education, collaboration, and advancing aesthetic medicine through scalable, high-quality care models.

Through the collaboration, Alpha will conduct a multi-site evaluation of Obagi® saypha® MagIQ™ across its network of practices. The program will use Alpha’s strengths in education, patient satisfaction, and cross-practice culture to generate evidence demonstrating the value of integrating Obagi’s injectable hyaluronic acid filler into diverse clinical environments.

According to John Wheeler, CEO of Alpha Aesthetics Partners, Obagi’s emphasis on real-world data and a thoughtful look at how skincare and injectables can work together to drive better outcomes for patients and providers stood out.

The ALOHA Program is designed to evaluate both clinical performance and patient experience, while supporting providers with complete Obagi protocols aimed at deepening patient relationships and driving consistent, high-quality outcomes. Standardized data will be collected across participating Alpha practices, with initial findings scheduled to be presented at the upcoming Alpha Summit. Results will also be shared at key industry conferences to highlight the real-world impact of introducing a new injectable across a leading network of aesthetic practices.

Drew Fine, U.S. General Manager, Professional Channel, said that partnering with an innovative leader like Alpha underscores Obagi’s commitment to launching new aesthetics solutions grounded in meaningful real-world evidence.

Obagi® saypha® ChIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix. The technology is designed to deliver natural-looking results with category-leading performance, including high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile.

Obagi Medical is an advanced skincare line rooted in research and skin biology. Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage.

Founded in 2023, Alpha Aesthetics Partners aims to advance the medical aesthetics industry through partner support and clinical training. Alpha Aesthetics Partners focuses on making medical spa ownership simpler and more collaborative, allowing partners to concentrate on providing patient care. The company is a portfolio company of Thurston Group, with a presence across 31 locations in 12 states.

Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth brands. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform, expertise in managing global beauty brands at scale, a balanced portfolio, asset light efficiency, and the market responsiveness and speed of entrepreneurial indie brands.

For more information about ALOHA, visit https://obagi-professional.com/.

Source: Waldencast plc

×

Welcome!

Smallcap Reporter is the source most up-to-date real-time, direct-from-source News Tips and Story Leads.

By Subscribing you will receive Daily Smallcap Update each day at 9:30 am ET (Market Open) in your inbox and you can unsubscribe any time.